Tyrosine kinase inhibitors differentially deregulate expression of metallothionein sub/isoforms in triple-negative breast cancer cells

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F62156489%3A43210%2F20%3A43919613" target="_blank" >RIV/62156489:43210/20:43919613 - isvavai.cz</a>

Výsledek na webu

<a href="https://mnet.mendelu.cz/mendelnet2020/mnet_2020_full.pdf" target="_blank" >https://mnet.mendelu.cz/mendelnet2020/mnet_2020_full.pdf</a>

DOI - Digital Object Identifier

—

Jazyk výsledku

angličtina

Název v původním jazyce

Tyrosine kinase inhibitors differentially deregulate expression of metallothionein sub/isoforms in triple-negative breast cancer cells

Popis výsledku v původním jazyce

Metallothionein (MT) expression has been tied to drug resistance in cancer cells. The MT isoforms have also been investigated in connection to tyrosine kinase inhibitor (TKI) treatment - especially with sorafenib. Our work is focused on three different TKIs - vandetanib, lenvatinib and cabozantinib. Our aim was to investigate the effect of these TKIs on the expression of MT isoforms in breast cancer cell lines. We performed gene expression analysis of seven MT isoforms after TKI treatment. The analysis revealed that each TKI had a different impact on each cell line. Cabozantinib seemed to induce the biggest response of MT expression out of the three inhibitors, with fold change of MT1F and MT1G reaching 1.68 and 1.62, respectively, in MDA-MB-468 after 24h treatment. Lenvatinib, on the other hand, downregulated MT1X in the same cell line after 72h 0.48-fold. Similarly to MDA-MB-468, cabozantinib treatment upregulated MT1E and MT1X in MDA-MB-231 after 72h treatment, with 1.68 and 1.87-fold difference, respectively.

Název v anglickém jazyce

Tyrosine kinase inhibitors differentially deregulate expression of metallothionein sub/isoforms in triple-negative breast cancer cells

Popis výsledku anglicky

Metallothionein (MT) expression has been tied to drug resistance in cancer cells. The MT isoforms have also been investigated in connection to tyrosine kinase inhibitor (TKI) treatment - especially with sorafenib. Our work is focused on three different TKIs - vandetanib, lenvatinib and cabozantinib. Our aim was to investigate the effect of these TKIs on the expression of MT isoforms in breast cancer cell lines. We performed gene expression analysis of seven MT isoforms after TKI treatment. The analysis revealed that each TKI had a different impact on each cell line. Cabozantinib seemed to induce the biggest response of MT expression out of the three inhibitors, with fold change of MT1F and MT1G reaching 1.68 and 1.62, respectively, in MDA-MB-468 after 24h treatment. Lenvatinib, on the other hand, downregulated MT1X in the same cell line after 72h 0.48-fold. Similarly to MDA-MB-468, cabozantinib treatment upregulated MT1E and MT1X in MDA-MB-231 after 72h treatment, with 1.68 and 1.87-fold difference, respectively.

Druh

D - Stať ve sborníku

CEP obor

—

OECD FORD obor

10608 - Biochemistry and molecular biology

Projekt

<a href="/cs/project/GA18-10251S" target="_blank" >GA18-10251S: Komplexní pohled na mechanismus působení a metabolismus inhibitorů tyrosinkinas a studium přístupů k potenciaci jejich protinádorové účinnosti</a><br>

Návaznosti

P - Projekt vyzkumu a vyvoje financovany z verejnych zdroju (s odkazem do CEP)

Rok uplatnění

2020

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název statě ve sborníku

MendelNet 2020: Proceedings of International PhD Students Conference

ISBN

978-80-7509-765-1

ISSN

—

e-ISSN

—

Počet stran výsledku

5

Strana od-do

562-566

Název nakladatele

Mendelova univerzita v Brně

Místo vydání

Brno

Místo konání akce

Brno

Datum konání akce

11. 11. 2020

Typ akce podle státní příslušnosti

WRD - Celosvětová akce

Kód UT WoS článku

—